Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma

Gaurav C. Parikh, Ali Imran Amjad, Rima M. Saliba, Syed M A Kazmi, Ziad U. Khan, Amit Lahoti, Chitra Hosing, Floralyn Mendoza, Suhail R. Qureshi, Donna M. Weber, Michael Wang, Uday Popat, Amin M. Alousi, Richard E. Champlin, Sergio A. Giralt, Muzaffar H. Qazilbash

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


Approximately 20% of patients with multiple myeloma (MM) have renal failure at diagnosis, and about 5% are dialysis-dependent. Many of these patients are considered ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) because of a high risk of treatment-related toxicity. We evaluated the outcome of 46 patient with MM and renal failure, defined as serum creatinine >2 mg/dL sustained for >1 month before the start of preparative regimen. Patients received auto-HSCT at our institution between September 1997 and September 2006. Median serum creatinine and creatinine clearance (CrCl) at auto-HSCT were 2.9 mg/dL (range: 2.0-12.5) and 33 mL/min (range: 8.7-63), respectively. Ten patients (21%) were dialysis-dependent. Median follow-up in surviving patients was 34 months (range: 5-81). Complete (CR) and partial responses (PR) after auto-HSCT were seen in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall response rate of 75%. Two patients (4%) died within 100 days of auto-HSCT. Grade 2-4 nonhematologic adverse events were seen in 18 patients (39%) and included cardiac arrythmias, pulmonary edema, and hyperbilirubinemia. Significant improvement in renal function, defined as an increase in flomerular filtration rate (GFR) by 25% above baseline, was seen in 15 patients (32%). Kaplan-Meier estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 36% and 64%, respectively. In conclusion, auto HSCT can be offered to patients with MM and renal failure with acceptable toxicity and with a significant improvement in renal function in approximately one-third of the transplanted patients. In this analysis, a melphalan (Mel) dose of 200 mg/m2 was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM).

Original languageEnglish (US)
Pages (from-to)812-816
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Issue number7
StatePublished - Jul 2009


  • Autologous
  • Myeloma
  • Renal failure

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma'. Together they form a unique fingerprint.

Cite this